Clinical efficacy and safety of L -carnitine and coenzyme Q10 in treatment of severe chronic heart failure
10.13699/j.cnki.1001-6821.2015.20.003
- VernacularTitle:左卡尼汀联合辅酶 Q10治疗重症慢性心力衰竭的临床疗效及安全性评价
- Author:
Yong DING
1
;
Xiu-Ling YANG
Author Information
1. 河南大学医学院
- Keywords:
L-carnitine;
coenzyme Q10;
chronic heart failure;
cardiac function
- From:
The Chinese Journal of Clinical Pharmacology
2015;(20):1993-1995
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical effect and safety of L-carnitine and coenzyme Q10 on the treatment of chronic heart failure. Methods One hundred ninety-six patients with chronic heart failure cardiacⅢ-Ⅳlevel were paired by age and gender, and each pair were randomly divided into experimental group and the control group, every group has 98 patients.The control group was treated with metoprolol 100 mg, bid +chlorine 50 mg qd +spironolactone 40 mg bid conventional heart failure treatment.The experimental group was added with L-carni-tine (20 mg? kg -1 ,bid) and coenzyme Q10 (10 mg tid) on the basis of conventional treatment. After treatment, the improvement of cardiac function and incidence of adverse drug reactions between the two groups were compared. Results The total effective rate of treatment group (89.80%) is significantly higher than that in control group 63.27%(P<0.05).After treatment, the C reactive protein content and the brain natriuretic peptide ( BNP) level of experimental group were signifi-cantly lower than those in control group ( P<0.05).6 min walking dis-tance of patients in experimental group is longer than that in control group.The left ventricular ejection fraction ( LVEF) of treatment group was significantly higher than that in control group and the left ventricular diastolic diameter ( LVEDD) and left ventricular end systolic diameter ( LVESD) significantly lower than those of control group.The adverse reactions between the two groups have no significant difference (P>0.05).Conclusion L-carnitine combined coenzyme Q10 can significantly improve the treatment effect of severe chronic heart failure without increasing of the incidence of adverse drug reactions.
